From Politics To Industry Reputation – Top Of Mind Topics For Execs In Biopharma
In preparing for this year’s annual outlook issue (published in December), Life Science Leader posed a variety of questions to biopharmaceutical executives. Unfortunately, not all the responses could be squeezed into the annual outlook print edition, so we decided to share them here. Don’t miss out on all the other knowledge and wisdom provided by the more than 40 biopharmaceutical executives taking part in this year’s annual outlook by becoming a Life Science Leader subscriber today.
How Do You Anticipate The Current State Of U.S Political Affairs Will Affect Biopharma In The U.S. And Globally In 2022 And Beyond?
Ivan Dimov, Ph.D., cofounder and CEO, Orca BioIvan Dimov, Ph.D., cofounder and CEO, Orca Bio: I'm concerned with the fragmentation around the world. At the macro level, we’ve seen the U.S. put up national barriers that did not exist in the 1990s and 2000s and other countries have followed suit. Although I do not believe that globalization is an unmitigated force for good, ultimately, cooperation between
countries is better for an industry like ours given its global and collaborative nature. Even on the individual level, as we’ve seen with the U.S. COVID-19 vaccination campaign, many people are only thinking about themselves and are not thinking about their communities. I think both dynamics are deeply destabilizing. Increased nationalism and individualism will make it harder for companies in our industry to collaborate with our peers across borders or even run clinical trials abroad. Ultimately,
